A US Food and Drug
Administration advisory panel has
voted to ease current restrictions
on the use of GlaxoSmithKline’s
Avandia (rosiglitazone) for the
treatment of type 2 diabetes.
The controversial decision
followed two days of deliberations,
with 13 of the 26 panel members
voting to modify the current
warning for the drugs, and another
7 voting to remove it altogether.
Previously FDA had restricted the
use of Avandia to patients whose
diabetes was not adequately
controlled by other medications, or
were already using the drug when
the restriction became effective in
Sep 2010.
The FDA restrictions were based
on an analysis of data which
suggested an elevated risk of heart
attacks in patients treated with
rosiglitazone.The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jun 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.